The central response to ovarian carcinoma simulates the response to sepsis

Journal of Surgical Research

Volumn 75, Issue 2, 1998, Pages 97-102

  Carson, Linda F ^b,c   Roy, Sabita ^a,b,c   Cain, Kelly ^a,c   Charboneau, Richard ^a,c   Deturris, Stanley ^a,c   Ramakrishin, S ^b   Barke, Roderick A ^a,b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

c fos; IL 1; IL 6; Ovarian carcinoma

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; CACHEXIA; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; GENE EXPRESSION; HYPERMETABOLISM; IMMUNE RESPONSE; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SIGNAL TRANSDUCTION;

EID: 0031798785     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5183     Document Type: Article

References (25)

1. Bast R. C. Jr. Principles of cancer biology: Tumor immunology. Cancer Principles and Practice of Oncology. 1985;Lippincott, Philadelphia. p. 141.
2. Dickerson R. N., White K. G., Curcillo P. G. II, King S. A., Mullen J. L. Resting energy expenditure of patients with gynecologic malignancies [see comments]. J. Am. Coll. Nutr. 14:1995;409-410.
3. Erroi A., Sironi M., Chiaffarino F. IL-1 and IL-6 release by tumor associated macrophages from human ovarian carcinoma. Int. J. Cancer. 44:1989;795-801.
4. Barke R. A., Roy S., Chapin R. B., Charboneau R., Brady P. S., Brady L. J. Sepsis-induced release of interleukin-6 may activate the immediate early gene program through a hypothalamic hypophyseal mechanism. Surgery. 116:1994;141-149.
5. Hill A. G., Gonzalez J., Rounds J. D., Wilmore D. W. Chronic central nervous system exposure to interleukin-1, but not interleukin-6, mediates catabolism in the rat. Surg. Forum. XLV:1994;38-41.
6. Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156.
7. Chapin R. B., Roy S., Charboneau R., Cain K., Brady P. S., Brady L. J., Barke R. A. Regulation of the transcription factor C/EBPα following peritoneal sepsis. J. Surg. Res. 59:1995;460-467.
8. Senba E., Umemoto S., Kawai Y., Noguchi K. Differential expression offosjun. Brain Res. Mol. Brain Res. 24:1994;283-294.
9. Ericsson A., Sawchenko P. E. c-fos based functional mapping of central pathways subserving effects of interleukin-1 on the hypothalamo-pituitary-adrenal axis. De Souza E. B. Neurobiology of Cytokines (Part A). 1993;155-172 Academic Press, New York.
10. Katsuura G., Gottschall P. E., Dahl R. R., Arimura A. Interleukin-1 beta increases prostaglandin E2 in rat astrocyte cultures: Modulatory effect of neuropeptides. Endocrinology. 1124:1989;3125-3127.
11. Vankelecom H., Carmeliet P., Van-Damme J., Billiau A., Denef C. Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology. 49:1989;102-106.
12. Alam T., An M. R., Papaconstantinou J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. J. Biol. Chem. 267:1992;5021-5024.
13. McKnight S. L., Lane D. M., Gluecksonh-Walsh S. Is CCAAT/enhancer binding protein a central regulator of energy metabolism. Gene Dev. 3:1989;2021-2024.
14. McKnight S. L. CCAAT/enhancer binding protein. McKnight S. L. Transcriptional Regulation. 1992;771-796 Cold Spring Harbor Laboratory Press, Plainview.
15. Umek R. M., Friedman A. D., McKnight S. I. CCAAT enhancer binding protein: A component of a differentiation switch. Science. 251:1991;288-292.
16. Freytag S. O. Enforced expression of thec-myc. Mol. Cell Biol. 8:1988;1614-1624.
17. Freytag S. O., Dang C. V., Lee W. M. Definition of the activities and properties ofc-myc. Cell Growth Differ. 1:1990;339-343.
18. Christy R. J., Kaestner K. H., Geiman D. E., Lane M. D. CCAAT/enhancer binding protein gene promoter: Binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA. 88:1991;2593-2597.
19. Blackwell T. K., Kretzner L., Blackwood E. M., Eisenman R. N. Sequence-specific DNA binding by thec-myc. Science. 1250:1990;1149-1151.
20. Rivier C., Vale W., Brown M. In the rat, interleukin-1 alpha and -beta stimulate adrenocorticotropin and catecholamine release. Endocrinology. 125:1989;3096-3102.
21. Uehara A., Gottschall P. E., Dahl R. R., Arimure A. Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology. 121:1987;1580-1582.
22. Boutillier A. L., Sassone-Corsi P., Loeffler J. P. The protooncogenec-fos. Mol. Endocrinol. 5:1991;1301-1310.
23. Onsrud M. Serum-mediated immunosuppression: A possible tumor marker in patients with ovarian carcinoma. Gynecol. Oncol. 21:1985;94-100.
24. Marotti T., Hrsak I., Krusic J., Deveric G. Immunosuppression related to ascitic fluid in patients with ovarian carcinoma. Oncology. 39:1982;298-303.
25. Ueda K., Toyokawa M., Nakamori H., Sako H., Umesaki N., Nakade J., Lee T., Sugawa T. Immunosuppressive effect of serum in patients with ovarian carcinoma. Obstet. Gynecol. 51:1978;225-228.